NCT05849272View on ClinicalTrials.gov

Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 12, 2023

Primary Completion Date

May 8, 2024

Study Completion Date

May 8, 2024

Conditions
Somatic Symptom
Interventions
DRUG

toludesvenlafaxine hydrochloride sustained-release tablets

orally once a day

Trial Locations (1)

200030

Shanghai Mental Health Center, Shanghai

All Listed Sponsors
lead

Shanghai Mental Health Center

OTHER

NCT05849272 - Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression | Biotech Hunter | Biotech Hunter